Medscape:缺乏维生素D对人类健康的影响

2015-01-09 MedSci MedSci原创

一些前瞻性流行病学研究显示较低的血清维生素D水平与全球认知功能的迅速的下降,以及痴呆和阿尔茨海默症的发展有关联。回顾最近的9个流行病学的研究,对健康知识了解较少的人群的血清水平浓度为10 ng/mL。目前还不太清楚补充多少维生素D会改善认知或防止老年人认知水平下降,还没有随机临床试验数据来支持通过补充维生素改善认知或防止衰老。 在妇女健康倡议的记忆研究中,超过7.8年的时间内给一个随机样本的女性

一些前瞻性流行病学研究显示较低的血清维生素D水平与全球认知功能的迅速的下降,以及痴呆和阿尔茨海默症的发展有关联。回顾最近的9个流行病学的研究,对健康知识了解较少的人群的血清水平浓度为10 ng/mL。目前还不太清楚补充多少维生素D会改善认知或防止老年人认知水平下降,还没有随机临床试验数据来支持通过补充维生素改善认知或防止衰老。

在妇女健康倡议的记忆研究中,超过7.8年的时间内给一个随机样本的女性补充钙和400国际单位的维生素D3并没有导致功能上的差异(注意、工作记忆、词汇知识,空间能力,言语流利,口头记忆,具有人的形象的记忆,或精细的运动速度)。此外,在观察性研究中,人体内25位羟基维生素D水平很高,特别是在服用维生素D补充剂时, 在注意力测试上它被认为与认知障碍有关联,呈现出一个可能的U型曲线关系。

最近,美国预防服务工作组审查了维生素D缺乏症的证据,推断目前的证据是“对无症状缺乏维生素D的成年人进行筛查,不足以评估筛查的利与弊。”一部分推荐理由缺乏研究,而是用一种国际公认的参考标准和缺乏共识的实验数值来定义维生素D的缺乏。

总之,最好的调查研究建议对于18-70岁的成年人每日膳食摄入600国际单位的维生素D,70岁以上成年人服用800国际单位的维生素D, (市面上所卖的为1000国际单位)。骨软化症患者的维生素D水平应该得以保持(如扩散骨和关节疼痛、骨折、肌肉无力、走路困难),特别是在吸收不良的状态,在开始静脉注射二磷酸盐治疗骨质疏松症前,因为潜在的诱发低钙血症的维生素D缺乏症患者会接受这些药物。目前还没有迹象表明通过筛查无症状患者的维生素D水平而进行维生素D补充,用以防止患者认知的变化。

原始出处

David B. Reuben, MD. Vitamin D Screening: What About the Adult With Cognitive Changes? MedScape.2014

本文是MedSci原创编译整理,欢迎转载! 转载请注明来源并附原文链接。谢谢!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1897970, encodeId=4e8d189e970da, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sat Jan 24 09:30:00 CST 2015, time=2015-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1694516, encodeId=44f816945164a, content=<a href='/topic/show?id=2dde25041f2' target=_blank style='color:#2F92EE;'>#人类健康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25041, encryptionId=2dde25041f2, topicName=人类健康)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon Dec 14 06:30:00 CST 2015, time=2015-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725719, encodeId=7bab1e25719c5, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Apr 19 13:30:00 CST 2015, time=2015-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350968, encodeId=e1d313509684c, content=<a href='/topic/show?id=f5a31596056' target=_blank style='color:#2F92EE;'>#SCAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15960, encryptionId=f5a31596056, topicName=SCAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jan 11 04:30:00 CST 2015, time=2015-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458568, encodeId=5cfc14585684b, content=<a href='/topic/show?id=6b5511492e2' target=_blank style='color:#2F92EE;'>#Medscape#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11492, encryptionId=6b5511492e2, topicName=Medscape)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4ab6090887, createdName=bnjfx@128.com, createdTime=Sun Jan 11 04:30:00 CST 2015, time=2015-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606370, encodeId=c65f16063e037, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jan 11 04:30:00 CST 2015, time=2015-01-11, status=1, ipAttribution=)]
    2015-01-24 smlt2008
  2. [GetPortalCommentsPageByObjectIdResponse(id=1897970, encodeId=4e8d189e970da, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sat Jan 24 09:30:00 CST 2015, time=2015-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1694516, encodeId=44f816945164a, content=<a href='/topic/show?id=2dde25041f2' target=_blank style='color:#2F92EE;'>#人类健康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25041, encryptionId=2dde25041f2, topicName=人类健康)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon Dec 14 06:30:00 CST 2015, time=2015-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725719, encodeId=7bab1e25719c5, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Apr 19 13:30:00 CST 2015, time=2015-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350968, encodeId=e1d313509684c, content=<a href='/topic/show?id=f5a31596056' target=_blank style='color:#2F92EE;'>#SCAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15960, encryptionId=f5a31596056, topicName=SCAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jan 11 04:30:00 CST 2015, time=2015-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458568, encodeId=5cfc14585684b, content=<a href='/topic/show?id=6b5511492e2' target=_blank style='color:#2F92EE;'>#Medscape#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11492, encryptionId=6b5511492e2, topicName=Medscape)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4ab6090887, createdName=bnjfx@128.com, createdTime=Sun Jan 11 04:30:00 CST 2015, time=2015-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606370, encodeId=c65f16063e037, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jan 11 04:30:00 CST 2015, time=2015-01-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1897970, encodeId=4e8d189e970da, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sat Jan 24 09:30:00 CST 2015, time=2015-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1694516, encodeId=44f816945164a, content=<a href='/topic/show?id=2dde25041f2' target=_blank style='color:#2F92EE;'>#人类健康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25041, encryptionId=2dde25041f2, topicName=人类健康)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon Dec 14 06:30:00 CST 2015, time=2015-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725719, encodeId=7bab1e25719c5, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Apr 19 13:30:00 CST 2015, time=2015-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350968, encodeId=e1d313509684c, content=<a href='/topic/show?id=f5a31596056' target=_blank style='color:#2F92EE;'>#SCAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15960, encryptionId=f5a31596056, topicName=SCAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jan 11 04:30:00 CST 2015, time=2015-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458568, encodeId=5cfc14585684b, content=<a href='/topic/show?id=6b5511492e2' target=_blank style='color:#2F92EE;'>#Medscape#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11492, encryptionId=6b5511492e2, topicName=Medscape)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4ab6090887, createdName=bnjfx@128.com, createdTime=Sun Jan 11 04:30:00 CST 2015, time=2015-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606370, encodeId=c65f16063e037, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jan 11 04:30:00 CST 2015, time=2015-01-11, status=1, ipAttribution=)]
    2015-04-19 feather89
  4. [GetPortalCommentsPageByObjectIdResponse(id=1897970, encodeId=4e8d189e970da, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sat Jan 24 09:30:00 CST 2015, time=2015-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1694516, encodeId=44f816945164a, content=<a href='/topic/show?id=2dde25041f2' target=_blank style='color:#2F92EE;'>#人类健康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25041, encryptionId=2dde25041f2, topicName=人类健康)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon Dec 14 06:30:00 CST 2015, time=2015-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725719, encodeId=7bab1e25719c5, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Apr 19 13:30:00 CST 2015, time=2015-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350968, encodeId=e1d313509684c, content=<a href='/topic/show?id=f5a31596056' target=_blank style='color:#2F92EE;'>#SCAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15960, encryptionId=f5a31596056, topicName=SCAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jan 11 04:30:00 CST 2015, time=2015-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458568, encodeId=5cfc14585684b, content=<a href='/topic/show?id=6b5511492e2' target=_blank style='color:#2F92EE;'>#Medscape#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11492, encryptionId=6b5511492e2, topicName=Medscape)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4ab6090887, createdName=bnjfx@128.com, createdTime=Sun Jan 11 04:30:00 CST 2015, time=2015-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606370, encodeId=c65f16063e037, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jan 11 04:30:00 CST 2015, time=2015-01-11, status=1, ipAttribution=)]
    2015-01-11 zhaojie88
  5. [GetPortalCommentsPageByObjectIdResponse(id=1897970, encodeId=4e8d189e970da, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sat Jan 24 09:30:00 CST 2015, time=2015-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1694516, encodeId=44f816945164a, content=<a href='/topic/show?id=2dde25041f2' target=_blank style='color:#2F92EE;'>#人类健康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25041, encryptionId=2dde25041f2, topicName=人类健康)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon Dec 14 06:30:00 CST 2015, time=2015-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725719, encodeId=7bab1e25719c5, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Apr 19 13:30:00 CST 2015, time=2015-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350968, encodeId=e1d313509684c, content=<a href='/topic/show?id=f5a31596056' target=_blank style='color:#2F92EE;'>#SCAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15960, encryptionId=f5a31596056, topicName=SCAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jan 11 04:30:00 CST 2015, time=2015-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458568, encodeId=5cfc14585684b, content=<a href='/topic/show?id=6b5511492e2' target=_blank style='color:#2F92EE;'>#Medscape#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11492, encryptionId=6b5511492e2, topicName=Medscape)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4ab6090887, createdName=bnjfx@128.com, createdTime=Sun Jan 11 04:30:00 CST 2015, time=2015-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606370, encodeId=c65f16063e037, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jan 11 04:30:00 CST 2015, time=2015-01-11, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1897970, encodeId=4e8d189e970da, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sat Jan 24 09:30:00 CST 2015, time=2015-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1694516, encodeId=44f816945164a, content=<a href='/topic/show?id=2dde25041f2' target=_blank style='color:#2F92EE;'>#人类健康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25041, encryptionId=2dde25041f2, topicName=人类健康)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Mon Dec 14 06:30:00 CST 2015, time=2015-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725719, encodeId=7bab1e25719c5, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Apr 19 13:30:00 CST 2015, time=2015-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350968, encodeId=e1d313509684c, content=<a href='/topic/show?id=f5a31596056' target=_blank style='color:#2F92EE;'>#SCAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15960, encryptionId=f5a31596056, topicName=SCAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jan 11 04:30:00 CST 2015, time=2015-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458568, encodeId=5cfc14585684b, content=<a href='/topic/show?id=6b5511492e2' target=_blank style='color:#2F92EE;'>#Medscape#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11492, encryptionId=6b5511492e2, topicName=Medscape)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4ab6090887, createdName=bnjfx@128.com, createdTime=Sun Jan 11 04:30:00 CST 2015, time=2015-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606370, encodeId=c65f16063e037, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Jan 11 04:30:00 CST 2015, time=2015-01-11, status=1, ipAttribution=)]

相关资讯

Acta Paediatrica:要想婴儿抵抗呼吸道感染 维生素D必不可少

据来自奥克兰大学的一项研究证实,婴儿的母亲在怀孕期服用维生素D补充剂的话,婴儿不太可能患呼吸道感染。该研究显示,相较于安慰剂组,孕期孕妇补充维生素D后,婴儿发生呼吸道感染的比例较小。这项研究结果最近发表在杂志Acta Paediatrica上。本次临床试验的主要目的,以确定维生素D的剂量对于怀孕期间孕妇是必要的,以防止婴儿维生素D不足。Grant博士说,仔细而彻底的审查基层医疗记录后,研究人员能够

Prostate:炎症或是维生素D和前列腺癌发病之间缺失的关键环节

近日,来自科罗拉多大学癌症中心的研究人员通过研究发现,炎症或许是连接维生素D和前列腺癌发病之间的一个关键点,相关研究发表于国际杂志The Prostate上。文章中,研究者指出,被维生素D上调的基因GDF-15或许在由炎症驱动的人类前列腺癌组织样本中是明显缺失的。 James R. Lambert博士表示,当服用维生素D并且作用于前列腺癌细胞时,维生素D就会抑制癌细胞的生长,但这并不能证明其

维生素D或有助调节人体生物钟

你在太阳底下待的时间够吗?在保持骨骼强壮的同时,维生素D或许还能帮助调节人体生物钟。 人们都拥有一小群在一天中会开启和关闭的“时钟基因”。因此,它们所编码的蛋白质水平在24小时内有升有降。强制实施的作息如夜班工作会让健康陷入混乱状态,例如增加脑卒中的风险。 为确认维生素D缺乏是否可能对此负责,来自墨西哥蒙特雷高等教育与技术学院的Sean-Patrick Scott和同事观

Diabetes Care:VD补充剂能否预防或延缓糖尿病发生?

一些观察性研究表明维生素D可以降低2型糖尿病的发病风险,但是缺乏长期的试验数据。维生素D和2型糖尿病(D2d)研究是一项随机的临床研究,为验证补充维生素D和糖尿病高风险人群发展为2型糖尿病之间是否存在因果关系,并验证补充维生素D是否安全有效地降低高风险糖尿病人群发展为2型糖尿病分的风险。研究内容及设计发表在《糖尿病医疗》上。 D2d的设计来自国家糖尿病、消化系统病和肾病研究所(NIDDK

Antioxid Redox Signal:阳光维生素造福心血管患者

近日,氧化应激生物医学领域最权威杂志《ANTIOXIDANTS & REDOX SIGNALING》(IF 7.7) 在线发表了仁济医院心内科何奔教授领衔团队的最新研究成果“Vitamin D receptor activation protects against myocardial reperfusion injury through inhibition of apoptosis

JCEM:维生素D及体能状态与身体组成及肌肉功能存在相关性:针对一个社区常驻老年人群的五年对比研究

研究背景: 在老年人群中,高水平维生素D及充分的体能活动(PA)能独立改善身体组成及肌肉功能。 研究设计: 本研究基于一项针对澳大利亚社区常驻老年人的5年前瞻性人群研究。 受试者: 从选民名册中随机抽取了50岁以上的615名社区常驻志愿者(61.4±6.9岁,女性占48%),根据基线25OHD水平(≥ 或 <50nmol/L)及PA水平(≥ 或 <计步